HK Stock Market Move | EVEREST MED (01952) rises over 3% as two new drugs enter medical insurance for the first time; Velsipity shows good safety in treating ulcerative colitis.

date
11:23 16/11/2026
avatar
GMT Eight
Everest Med (01952) rises over 3%. As of press time, it is up 3.45% at HK$26.42, with a turnover of HK$85.8234 million.
EVEREST MED (01952) rose over 3%, up 3.45% as of press time at HK$26.42, with turnover of HK$85.8234 million. On the news front, on November 14, EVEREST MED's Velsipity (etrasimod arginine tablets) and Xerava (eravacycline hydrochloride for injection) passed the national medical insurance negotiation and were included for the first time in the "National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2026)", with the new catalog to be officially implemented from January 1, 2027. At the same time, its IgA nephropathy disease-modifying therapy Nefecon (budesonide enteric-coated capsules) successfully renewed its contract and remains in the catalog. To date, EVEREST MED has three products included in the national medical insurance catalog, covering areas such as ulcerative colitis, complicated intra-abdominal infections, and IgA nephropathy, among which Velsipity was included in medical insurance in its first year on the market. It is reported that Velsipity is China's first and only approved sphingosine-1-phosphate (S1P) receptor modulator for the treatment of UC. In the largest Asian multicenter Phase III clinical study (ENLIGHT UC) conducted to date in patients with moderate-to-severe UC, Velsipity achieved a 52-week mucosal healing rate of 51.9%, and long-term follow-up showed good medication safety.